Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

NCT00365183 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT00365183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00365183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2006
Completion date
June 30, 2008
Enrollment
74 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma